Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently - A cohort and case-control study

被引:119
|
作者
Jones, R
Stebbing, J
Nelson, M
Moyle, G
Bower, M
Mandalia, S
Gazzard, B
机构
[1] Chelsea & Westminster Hosp, Dept HIV & Genitourinary Med, London SW10 9NH, England
[2] Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Div Invest Sci,Dept Immunol, Fac Med, London, England
关键词
tenofovir DF; highly active antiretroviral therapy; renal; cohort; creatinine;
D O I
10.1097/01.qai.0000138983.45235.02
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Tenofovir disoproxil fumarate (tenofovir DF), the first nucleotide analogue reverse transcriptase inhibitor approved for the treatment of HIV infection, has been associated with renal dysfunction in isolated cases. We investigated the overall incidence and risk of renal dysfunction in individuals receiving tenofovir DF and compared this with other antiretrovirals. Methods: Data from the Chelsea and Westminster cohort were analyzed to reveal HIV-positive individuals with a creatinine value greater than 120 mumol/L at any time, the upper limit of normal used by our reference laboratory. These individuals were classified according to antiretroviral exposure and time exposed. A matched case-control study was performed comparing patients who had received tenofovir DF and subsequently developed a creatinine value greater than 120 mumol/L against controls who had been treated with tenofovir DF and had not experienced a creatinine elevation. Results: Of 4183 HIV-positive patients, 1175 were identified as having a recorded creatinine value >120 mumol/L. Comparison of antiretroviral-naive patients and patients exposed to tenofovir DF- and non-tenofovir DF-containing regimens revealed a lower rate ratio and probability of developing a creatinine value >120 mumol/L in patients exposed to tenofovir DF (rate ratio vs. no antiretrovirals = 0.22, 95% confidence interval [CI]: 0.07-0.69; P < 0.001) with no significant difference between HAART regimens, corrected for duration of exposure. Of the 1058 individuals who were exposed to tenofovir DF, 84 (8%) patients experienced a creatinine value >120 mumol/L subsequent to exposure. An alternative etiology of renal dysfunction was found in 75 (90%) of these individuals. Conclusions: Tenofovir DF is not associated with renal dysfunction more frequently than other antiretroviral drugs, and the occurrence of renal dysfunction in this context is usually attributable to other causes.
引用
收藏
页码:1489 / 1495
页数:7
相关论文
共 24 条
  • [1] Renal outcomes with efavirenz plus tenofovir disoproxil fumarate/emtricitabine versus other tenofovir disoproxil fumarate-containing antiretroviral regimens among HIV-infected veterans: a national study
    LaFleur, J.
    Bress, A.
    Esker, S.
    Crook, J.
    Nyman, H.
    Bedimo, R.
    Tebas, P.
    Rosenblatt, L.
    [J]. ANTIVIRAL THERAPY, 2016, 21 : A60 - A60
  • [2] Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy
    Winston, A
    Amin, J
    Mallon, PWG
    Marriott, D
    Carr, A
    Cooper, DA
    Emery, S
    [J]. HIV MEDICINE, 2006, 7 (02) : 105 - 111
  • [3] Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy
    Nishijima, Takeshi
    Kurosawa, Takuma
    Tanaka, Noriko
    Kawasaki, Yohei
    Kikuchi, Yoshimi
    Oka, Shinichi
    Gatanaga, Hiroyuki
    [J]. AIDS, 2016, 30 (10) : 1563 - 1571
  • [4] Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults
    Agbaji, Oche O.
    Abah, Isaac O.
    Ebonyi, Augustine O.
    Gimba, Zumnan M.
    Abene, Esla E.
    Gomerep, Simji S.
    Falang, Kakjing D.
    Anejo-Okopi, Joseph
    Agaba, Patricia A.
    Ugoagwu, Placid O.
    Agaba, Emmanuel I.
    Imade, Godwin E.
    Sagay, Atiene S.
    Okonkwo, Prosper
    Idoko, John A.
    Kanki, Phyllis J.
    [J]. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE, 2019, 18
  • [5] Effects of long-term exposure to tenofovir disoproxil fumarate-containing antiretroviral therapy on renal function in HIV-positive Chinese patients
    Tan, Qing
    He, Yuan-Hong
    Yang, Tong-Tong
    Yan, Dong-Mei
    Wang, Yan
    Zhao, Xia
    Liu, Huan-Xia
    He, Sheng-Hua
    Zhou, Zhong-Hui
    [J]. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2019, 52 (05) : 710 - 719
  • [6] Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study
    Judd, Ali
    Boyd, Katherine L.
    Stoehr, Wolfgang
    Dunn, David
    Butler, Karina
    Lyall, Hermione
    Sharland, Mike
    Shingadia, Delane
    Riordan, Andrew
    Gibb, Di M.
    [J]. AIDS, 2010, 24 (04) : 525 - 534
  • [7] Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study
    Heron, Jack E.
    McManus, Hamish
    Vickers, Tobias
    Ryan, Kathleen
    Wright, Edwina
    Carter, Allison
    Stoove, Mark
    Asselin, Jason
    Grulich, Andrew
    Donovan, Basil
    Guy, Rebecca
    Varma, Rick
    Chen, Marcus
    Ryder, Nathan
    Lewis, David A.
    Templeton, David J.
    O'Connor, Catherine C.
    Gracey, David M.
    [J]. PLOS ONE, 2023, 18 (02):
  • [8] The 10-year safety and efficacy of a tenofovir disoproxil fumarate (TDF)-containing, once-daily highly active antiretroviral therapy (HAART)
    Herath, C.
    Cassetti, I.
    Madruga, J. V.
    Etzel, A.
    Suleiman, J. M.
    Zhou, Y.
    Rhee, M.
    Warren, D. R.
    [J]. HIV MEDICINE, 2011, 12 : 74 - 74
  • [9] Intramuscular depot medroxyprogesterone acetate accentuates bone loss associated with tenofovir disoproxil fumarate-containing antiretroviral therapy initiation in young women living with HIV (the BONE: CARE study): a prospective cohort study in Uganda
    Matovu, Flavia Kiweewa
    Kiwanuka, Noah
    Nabwana, Martin
    Scholes, Delia
    Musoke, Philippa
    Fowler, Mary Glenn
    Beksinska, Mags E.
    Pettifor, John M.
    Brown, Todd T.
    [J]. LANCET GLOBAL HEALTH, 2022, 10 (05): : E694 - E704
  • [10] Incidence and Risk Factors of Tenofovir Disoproxil Fumarate Induced Nephrotoxicity and Renal Function Recovery, a Hospital Case-Control Study
    Srisopa, Sirikan
    Kornjirakasemsan, Akarawat
    Treebupachatsakul, Pornpit
    Sonthisombat, Paveena
    [J]. INFECTION AND CHEMOTHERAPY, 2023, 55 (02): : 226 - 236